Program Goals
Immunotherapy of B-cell Malignancies
Evidence of GvL Effect From Allo-BMT
Clues to Disease Relapse After Allo-BMT: T cells in Graft and GVHD
Autologous Adoptive T-cell Therapy: Tumor-infiltrating Lymphocytes in Melanoma
Autologous T-cell Therapy: Melanoma
Generation of a Tumor-targeted CAR
Evolution in CAR Design
Second-generation CARs: In Vivo
Phase I: Patients With B-cell ALL Treated With Autologous T Cells Genetically Targeted to CD19
Study Design
Rapid Tumor Elimination and Recovery of Bone Marrow After 19-28-z CAR T-cell Therapy
Disease Characteristics and Outcomes
Studies of Relapsed B-cell ALL
CRS and Neurologic Toxicities
CRS Management
CD19 Expression at Baseline and at Relapse
University of Pennsylvania Clinical Trial Results
University of Pennsylvania Clinical Trial Results
Early Clinical Trial Results (NCI)
MSKCC Clinical Trial Results: CLL
The Hostile Tumor Microenvironment
Interleukin-12
IL-12-secreting CAR T Cells In Vivo Efficacy
IL-12-secreting CAR T Cells Are Resistant to Treg-mediated Inhibition In Vivo
Syngeneic EL4(hCD19) Tumor Model
19z1IRESIL-12-modified T Cells Secrete Biologically Active IL-12 and Exhibit Enhanced Targeted Cytotoxic Function and Resistance to Tregs
Complete Eradication of ID8(MUC-CD) Ovarian Tumors in Mice With MUC16-targeted T Cells Expressing IL-12
Abbreviations
Abbreviations (cont)
Abbreviations (cont)
Abbreviations (cont)
Abbreviations (cont)